Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ACACB | O00763 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25545681 | 0.80 | ALDH1A1 (0.57) | PARP10ALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL25139633 | 0.80 | PARP10 (0.53) | PARP10HRH3ALDH1A1KMT2AACACB | |
| SCHEMBL18101744 | 0.78 | PARP10 (0.47) | PARP10HRH3ALDH1A1KMT2AACACB | |
| SCHEMBL18101745 | 0.78 | PARP10 (0.47) | PARP10POLBHRH3ALDH1A1KMT2A | |
| SCHEMBL25184395 | 0.76 | PARP10 (0.49) | PARP10HRH3ALDH1A1ACACBLMNA | |
| SCHEMBL4938257 | 0.75 | SLC6A3 (0.54) | HRH3ALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL23782603 | 0.75 | LMNA (0.44) | LMNAPTGS1 | |
| SCHEMBL25545459 | 0.74 | PDE4D (0.49) | PARP10HRH3ALDH1A1KMT2AACACB | |
| SCHEMBL7430529 | 0.73 | GSK3B (0.44) | POLBALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL7599592 | 0.73 | PGR (0.49) | ALDH1A1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326746-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2025-10-23 | — | — | US | disclosed |
| US-12234231-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2025-02-25 | — | — | US | disclosed |
| EP-4392422-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-118103368-A | EIF4E inhibitors and uses thereof | 皮克医疗公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| WO-2023028235-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326746-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | PARP10 932/4885POLB 1778/4885HRH3 4680/4885 |
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | PARP10 932/4885POLB 1778/4885HRH3 4680/4885 |
| US-12234231-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | PARP10 932/4885POLB 1778/4885HRH3 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.